We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.00 | 0.75% | 1,351.50 | 1,351.00 | 1,352.00 | 1,353.00 | 1,341.00 | 1,341.00 | 1,034,529 | 10:11:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.37 | 55.61B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/2/2022 08:58 | GlaxoSmithKline (GSK) is now just months away from publishing results which it expects will show that its latest RSV jab is safe and effective. Data is due in early 2022, and the vaccine is expected to be approved and in use by next winter. Dr Jamila Louahed, the vice-president of vaccine research and development at GSK, told The Telegraph that the pharmaceutical company has been working towards this moment for decades, and is now on the verge of a breakthrough. “We have to wait for the data to be certain, but I am quite comfortable saying there is a high probability that the vaccine will work,” she said. | tradermichael | |
19/2/2022 06:30 | Nearly £6.5 million worth of free shares for 'performance'. Surely they owe it to ordinary shareholders to explain this performance if it is considered to be good or bad. | krowelet | |
18/2/2022 23:12 | This company is certainly not run in the best interest of the shareholders. | spoole5 | |
18/2/2022 22:13 | This ceo is massively overpaid.... More vesting of awards.... 412000 odd shares Most of the RNS for this company seem to relate to share awards all the time. Turns dowm an easy wedge of cash from Unilever... Pressure now on to make sure the demerger "works" | geckotheglorious | |
18/2/2022 14:51 | It will likely get a another kick in that direction next Thursday when they go ex-divi. £17+ looks very good from where we are now. | jonjoneil | |
18/2/2022 13:38 | Drifting towards 1500 by the split, the refusal looking more idiotic by the day. | spoole5 | |
18/2/2022 11:59 | Do you think these 'blokers' ever talk to each other? If you want a more realistic forecast - Emma says 'buy 2350'! | jonjoneil | |
18/2/2022 11:31 | 15-Feb-22 Liberum Capital Buy 1,910.00 (up from 1870p) | tradermichael | |
18/2/2022 10:42 | Ha Ha jj - it certainly made me feel better! | spyder | |
18/2/2022 10:40 | found the ref on LSE site. But no detail of course | jonjoneil | |
18/2/2022 10:17 | spyder do you have a link to the HSBC rating? I can't find any reference to it. You didn't make it up to make people like me feel better? | jonjoneil | |
18/2/2022 10:06 | Not sure that strategy will work this time around net ... | spyder | |
18/2/2022 09:47 | tempting for 1% dividend of pre-dividend bounce on monday/tuesday... early days. | netcurtains | |
18/2/2022 08:33 | Mixed news today, GSK has suspended its Phase III trials of its RSV vaccine in pregnant women, but, HSBC raises target price to 2170p from 2000p | spyder | |
17/2/2022 11:11 | The majority of the offer was cash | spoole5 | |
16/2/2022 21:53 | if we d had taken their shares in part payment that has gone down after the offer so we d have lost either way though not as much would have been fine if it was an all cash offer | billionairepaddy | |
16/2/2022 21:30 | Eloquently put and sadly very true!Like many I should have sold when it peaked over £17 | gateside | |
16/2/2022 17:05 | Deutsche marked GSK down to £15. I listened to Emma and now I'm confused. Anyone have access to their reasoning? | jonjoneil | |
16/2/2022 09:12 | Maybe Elliot is pulling some out ? | panache1 | |
16/2/2022 08:44 | I was thinking that too! | charlie9038 | |
16/2/2022 08:39 | Had to check it wasn't ex div! | spoole5 | |
15/2/2022 14:49 | My thoughts were indeed for those that fall into that category,as they say to whom it may or may not concern ! | abdullla | |
15/2/2022 14:17 | Have you missed a zero or two off that? | pander45 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions